Brightline-1 (1403.8): A Phase 2/3, randomized, open-label, multicenter study of brigimadlin (MDM2-p53 antagonist) compared with doxorubicin as first-line treatment of patients with advanced dedifferentiated liposarcoma^1–3

Zoom

1. Schöffski P, et al. Future Oncol. 2023;19:621–629; 2. NCT05218499. https://clinicaltrials.gov/ct2/show/NCT05218499. Accessed September 2023; 3. Boehringer Ingelheim. Data on file.